Evidence map›Paper›PMID 35163583›Full record

Trial reportInternational journal of molecular sciences2022

Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology.

Nagiua Cuomo-Haymour, Giorgio Bergamini, Giancarlo Russo, Luka Kulic, Irene Knuesel, Roland Martin, André Huss, Hayrettin Tumani, Markus Otto, Christopher R Pryce

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Perspective and Therapeutic Potential of the Noncoding RNA-Connexin Axis.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. RNA biomarkers for alcohol use disorder.Frontiers in molecular neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Nagiua Cuomo-HaymourPreclinical Laboratory for Translational Research into Affective Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8008 Zurich, Switzerland.
Giorgio BergaminiPreclinical Laboratory for Translational Research into Affective Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8008 Zurich, Switzerland.
Giancarlo RussoFunctional Genomics Centre Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, 8057 Zurich, Switzerland.
Luka KulicRoche Innovation Center Basel, Neuroimmunology Division, Roche Pharma Research and Early Development, 4070 Basel, Switzerland.
Irene KnueselRoche Innovation Center Basel, Neuroimmunology Division, Roche Pharma Research and Early Development, 4070 Basel, Switzerland.
Roland MartinNeuroimmunology and MS Research, Neurology Clinic, University Hospital Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-0982-1329
André HussDepartment of Neurology, University Hospital Ulm, 89081 Ulm, Germany.ORCID 0000-0002-2761-7591
Hayrettin TumaniDepartment of Neurology, University Hospital Ulm, 89081 Ulm, Germany.ORCID 0000-0002-1647-6201
Markus OttoDepartment of Neurology, University Hospital Halle, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Christopher R PrycePreclinical Laboratory for Translational Research into Affective Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, 8008 Zurich, Switzerland.ORCID 0000-0002-5614-4690
University of Zurich · CHRoche (Switzerland) · CHUniversity Hospital Ulm · DEMartin Luther University Halle-Wittenberg · DE

Funding

Roche (Switzerland) EPBA2183845-A17
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS). Its first clinical presentation (clinically isolated syndrome, CIS) is often followed by the development of relapsing-remitting MS (RRMS). The periphery-to-CNS transmission of inflammatory molecules is a major pathophysiological pathway in MS. This could include signalling via extracellular vesicle (EV) microRNAs (miRNAs). In this study, we investigated the serum EV miRNome in CIS and RRMS patients and matched controls, with the aims to identify MS stage-specific differentially expressed miRNAs and investigate their biomarker potential and pathophysiological relevance. miRNA sequencing was conducted on serum EVs from CIS-remission, RRMS-relapse, and viral inflammatory CNS disorder patients, as well as from healthy and hospitalized controls. Differential expression analysis was conducted, followed by predictive power and target-pathway analysis. A moderate number of dysregulated serum EV miRNAs were identified in CIS-remission and RRMS-relapse patients, especially relative to healthy controls. Some of these miRNAs were also differentially expressed between the two MS stages and had biomarker potential for patient-control and CIS-RRMS separations. For the mRNA targets of the RRMS-relapse-specific EV miRNAs, biological processes inherent to MS pathophysiology were identified using in silico analysis. Study findings demonstrate that specific serum EV miRNAs have MS stage-specific biomarker potential and contribute to the identification of potential targets for novel, efficacious therapies.

Indexed as

Gene Expression ProfilingGene Expression RegulationAdolescentAdultAgedBiomarkersExtracellular VesiclesFemaleHumansMaleMicroRNAsMiddle AgedMultiple Sclerosis, Relapsing-RemittingBiomarkersMicroRNAsbiomarkerclinically isolated syndromeextracellular vesiclesinflammationmicroRNApathophysiologyrelapsing–remitting multiple sclerosis

Identifiers

PMID35163583
PMCPMC8836256
OpenAlexW4210523387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.